Skip to main content

Autoinflammatory

ice cubes
It has certainly been an interesting EULAR congress, with lots of new data emerging on both novel and extant treatments. Something which really struck me was the data on two topical approaches.…
RT @Yuz6Yusof: #LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after W

Md Yuzaiful Md Yusof Yuz6Yusof

1 month ago
#LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after WK12. Phase 3 RCT of Baricitinib in paediatric JIA showed 76% met ACR30 at WK12. The Double-blind withdrawal showed less patients on Bari flared vs PBO (17% vs 51%) @RheumNow https://t.co/T0mSDkoHJo
RT @ericdeinmd: #EULAR2022 LB002
P3 Double-Blind W/d study: Baricitinib for JIA
⭐️All pts start in open label w good

Eric Dein ericdeinmd

1 month ago
#EULAR2022 LB002 P3 Double-Blind W/d study: Baricitinib for JIA ⭐️All pts start in open label w good benefit (1/2 with ACR70) ⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier @RheumNow https://t.co/apSSLqu1mp
RT @AurelieRheumo: JUVE-BASIS Baricitinib in JIA
Phase 3 RCT wk12

Cs or BioDMARDs IR

⚡️Time to disease flare HR 0.

Aurelie Najm AurelieRheumo

1 month ago
JUVE-BASIS Baricitinib in JIA Phase 3 RCT wk12 Cs or BioDMARDs IR ⚡️Time to disease flare HR 0.24 ⚡️JIA-ACR50% 63% ⚡️% flares 17% vs. 50% in PBO Safety profile similar than adults @RheumNow #EULAR2022 LB0002 https://t.co/dX3DpB4QHT
RT @synovialjoints: Quote of the day “Don’t be too quick to call it negative” by Marco Gattorno on looking for sys

Dr. Antoni Chan synovialjoints

1 month ago
Quote of the day “Don’t be too quick to call it negative” by Marco Gattorno on looking for systemic Autoinflammatory disease (SAID) when there is the clinical suspicion #EULAR2022 @RheumNow https://t.co/SjARIlDjtR
RT @drdavidliew: So what diet to follow with autoimmunity in mind?
So many, all with different instructions.

Let’s co

David Liew drdavidliew

1 month ago
So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ
RT @Janetbirdope: JAK will quiet Still’s disease? 7 w Still’s 4 refractory disease had benefit w #JAKi POS0014. Need

Janet Pope Janetbirdope

1 month ago
JAK will quiet Still’s disease? 7 w Still’s 4 refractory disease had benefit w #JAKi POS0014. Needs more data but looks promising most w partial response . 5 on #Tofacitinib and 2 w #Baricitinib. ⁦@eular_org⁩ #EULAR2022 POS0014 ⁦@RheumNow⁩ https://t.co/j9IRgT9XJf
RT @RichardPAConway: Brevet et al. SAPHO syndrome. Divided into bone group and joint/mixed group. Better response to bis

Richard Conway RichardPAConway

1 month ago
Brevet et al. SAPHO syndrome. Divided into bone group and joint/mixed group. Better response to bisphosphonate in bone group 60% vs 6%. Better response to DMARD in joint/mixed group 94% vs 40% @RheumNow #EULAR2022 POS1333 https://t.co/FfYBIEGGgJ
#EULAR2022 – Day 2 Report

A full day at EULAR with oral and poster presentations of abstracts in the morning and a pl

Dr. John Cush RheumNow

1 month ago
#EULAR2022 – Day 2 Report A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, and fibromyalgia.https://t.co/dpq5Het2rN https://t.co/NIfkjhHw86
×